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Abstract
Neutralization test is the most reliable method of evaluating immunity against viral diseases but there is no standard
procedure for mumps virus, with tests differing in the infectivity of the challenge virus, 50% plaque reduction or complete
inhibition of cytopathic effects (CPE), and usage of complement. A reliable, easy, and simple neutralization test for mumps
virus was developed in this study. A recombinant mumps virus expressing GFP was generated as a challenge virus.
Complement was added to the neutralizing mixture at 1:200 when stocked serum samples were used. Neutralizing antibody
titers were expressed as the reciprocal of the highest dilution that did not exceed two-fold of FU values (GFP expression) of
the cell control wells. A total of 1,452 serum samples were assayed by inhibition of GFP expression in comparison with those
examined by conventional 100% inhibition of CPE. 1,367 (94.1%) showed similar neutralizing antibody titers when examined
by both methods. The GFP expression inhibition assay, using a recombinant mumps virus expressing GFP, is a simple and
time- saving method.
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Introduction
Mumps virus is a single-stranded negative sense RNA virus,
belonging to the genus Rubulavirus of the family Paramyxoviridae.
The mumps virus genome encodes seven major proteins in the
following gene order: nucleocapsid (N), phospho (P), matrix (M),
fusion (F), small hydrophobic (SH), hemagglutinin-neuraminidase
(HN), and large (L) protein genes [1]. V and I proteins are also
produced from the P gene. There are two envelope glycoproteins,
F and HN. The HN protein is involved in the virus attachment to
sialic acid receptors on the surface of host cells. This leads to a
conformational change of HN which induces further conforma-
tional change of the F protein in the cascade reaction of cell fusion
[1,2]. Thus, mumps virus infection is initiated by the F and HN
proteins, and neutralizing epitopes are located on these proteins
[3,4].
An acute infection of mumps virus is characterized by self-
limiting demonstrable swelling of the parotid glands with
tenderness and several complications have been reported following
parotitis, including aseptic meningitis, deafness, orchitis, and
pancreatitis [1,5]. Mumps virus circulates throughout the world,
and genotype classification of the wild type is useful for identifying
the pathway of transmission [6]. Recently, circulating mumps
virus strains have been divided into 12 genotypes from A to N
(excluding E and M) based upon the sequence diversity of the SH
gene [7,8]. Currently circulating strains in Japan were divided into
four genotypes, B, G, J, and L [9].
The isolation of mumps virus is essential for the diagnosis of
patients and for monitoring the antigenicity of wild circulating
strains. The efficiency of virus isolation depends mainly upon the
infectious viral load in clinical samples and the sensitivity of the
cells used for isolation. Vero cells have been used, but isolation is
not always successful because of the low viral load, timing of
sample taking, and transportation. Several serological tests have
been employed for the diagnosis of mumps virus infections and,
among them, the enzyme-linked immuno-assay (EIA) was used to
detect IgM antibodies for diagnosis and IgG EIA to investigate
immune status [10,11]. EIA antibodies did not reflect protective
immunity and a neutralization test is the most sensitive way to
predict protective immunity [12,13]. Neutralization tests take a
long time to obtain results and involve several complicated
procedures [14,15]. The sensitivity of neutralization test was
enhanced when complement was added [15]. Recently, the
addition of complement was found to lead to deposition on the
surface of viral particles bound with antibodies and destroyed the
structure of mumps virus during the neutralization reaction [16].
Thus, the presence of complement seems to be essential for
neutralization testing against mumps virus. In this study, a
recombinant mumps virus expressing green fluorescent protein
(GFP) was generated and the requirement for complement was
examined using fresh and stocked sera.
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Materials and Methods
Mumps Virus Strain
The Hoshino vaccine seed strain KO3 was developed by
attenuation through 22 passages in chick embryonic cells from a
wild-type mumps virus isolated in 1972 [17]. Full-length cDNA
was constructed from KO3 Hoshino. The GFP sequence was
inserted between the P/V and M genes (Fig. 1). GFP Hoshino was
recovered from 293 T cells transfected with N, P, and L expression
plasmids, and full-length cDNA under the control of T7 RNA
polymerase [18]. Monolayer of Vero cells was infected with GFP
Hoshino at m.o.i = 0.01 and culture fluid was stocked for challenge
virus.
Virus Infectivity
Vero cells were propagated in minimum essential medium
(MEM) supplemented with 5% fetal bovine serum (FBS).
Infectivity was determined based on the TCID50 in Vero cells.
The virus culture fluid was serially diluted by 10-fold and a
confluent monolayer of Vero cells was infected with 100 ml of each
dilution in 96-well plates. The plates were incubated for 2 h at
37uC in 5% CO2 and MEM supplemented with 2% FBS was
added. Infectivity was determined after incubation for 7 days.
Serum Samples
Eight serum samples obtained from healthy adults aged 23 to 58
years during a routine health check were used for the experiments
after obtaining verbal informed consent. The remaining portion of
the sera was used for preliminary experiments or as in-house
control serum. Stocked serum samples (n = 185) were obtained to
assess immunity against measles, mumps, rubella, and chickenpox
among new students of the nursing school of Ashikaga Red Cross
Hospital, Tochigi prefecture. The serological study was approved
by the ethics committee of the hospital and verbal informed
consent was obtained. Fresh serum samples (n = 1,452) obtained to
evaluate immunity against measles, mumps, rubella, and chick-
enpox among new students in primary, junior high, and high
schools, were used for routine yearly immunological assessments of
infection control and to advise regarding vaccination for antibody
negative pupils. The serological study was approved by the Health
Care Center of Keio University. The purpose of the study was
explained and written informed consent was obtained from their
guardians. Serum samples were anonymously transferred to our
laboratory, labeled with simplified numbers.
Virus Neutralization Test
The fresh serum samples were divided into several aliquots and
stocked at 220uC. The samples were kept at 56uC for 30 min to
inactivate the complement, serially diluted by 2-fold starting from
1:4, and mixed with the same volume of GFP Hoshino containing
100 TCID50 of infectious virus at 37uC for 90 min for
neutralization. The mixture was placed in 96-well plates in
duplicate for each dilution and 25,000 Vero cells were seeded in
0.1 ml. The plates were incubated for 7 days. In order to calculate
the titers automatically, the plates were processed to detect
fluorescence intensity (Fluoro-Units: FU) at an emission wave-
length of 528 nm and excitation wavelength of 485 nm using a
fluorescence reader, FLx800 (Bio-Tek Instruments, Vermont,
USA), similar to a method used to detect measles neutralizing
antibodies [19]. To evaluate the requirement of complement,
various concentrations of guinea pig complement (Denka Seiken,
Tokyo, Japan) were added to the neutralization mixture of serially
Figure 1. Genome construction of the recombinant mumps Hoshino strain expressing GFP and expression of GFP. Vero cells were
infected with GFP Hoshino mumps strain at m.o.i. = 0.02 and subjected to experiments for GFP expression with fluoro EIA and microscopic
examination on day 1, 3 and 5 of infection in comparison with mock-infection. Infectivity was assayed in culture supernatants on day 1, 3, and 5 of
infection.
doi:10.1371/journal.pone.0065281.g001
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diluted serum with challenge virus. Neutralizing antibody titers
were determined as the reciprocal of the highest dilutions that did
not exceed two-fold of FU values (GFP expression) of the cell
control wells. Conventional neutralizing antibody titers were
expressed as the reciprocal of the serum dilutions that showed
100% inhibition of CPE. Infectivity titer of the challenge virus was
back-titrated in each assay, showing 50–120 TCID50.
Statistical Analysis
Statistical significance in the neutralizing antibody titers was
examined between two groups by the Mann-Whitney test. A co-




GFP expression and the viral growth are shown in Fig. 1. Vero
cells were infected with the GFP Hoshino strain in a 24-well plate,
and culture fluids were obtained 1, 3, and 5 days later. A peak
infective titer of 104 TCID 50/ml was obtained 3 days after
infection. Mean GFP expression (FU) is shown with 1.0 standard
deviation (SD) in four wells in comparison with mock-infected
wells. Mock-infected wells showed approximately 300 FU during
the experiment, and GFP expression in infected wells increased to
peak (1,300 FU) on day 5 of infection. Together with FU in fluoro-
ELISA, fluoro-microscopic findings of CPE expansion with GFP
expression are also shown in Fig. 1. Few CPE were observed on
day 3 of infection and extensive cell fusion was noted on day 5.
The development of CPE was closely related to GFP expression.
Neutralizing Antibody Titers
The results of the neutralization tests are shown in Fig. 2. Serum
samples were serially diluted 2-fold from 1:4 to 1:256, and mixed
with the challenge virus. The NT assay was done in duplicate. The
results for one serum sample are shown in Fig. 2. CPE were
observed in one well at 1:32 and none at 1:16. The conventional
neutralizing antibody titer was considered to be 1:16 for 100%
inhibition of CPE. The mean FU of cell control wells (mock-
infected wells) was 202 FU. The mean FU of serial dilutions from
1:4 to 1:256 was 252 FU, 239 FU, 234 FU, 450 FU, 543 FU, 581
FU, and 591 FU, respectively. GFP expression increased to 450
FU at 1:32 and thus the neutralizing antibody titer for the GFP
expression assay was 1:16 for inhibition of the growth of GFP
Hoshino. The infective titers of the challenge virus were back-
titrated, showing 50–120 TCID 50. When CPE appeared in
.20% of the wells, GFP expression was .500 FU.
To evaluate the consistency of neutralizing antibody titers
assayed by 100% inhibition of the appearance of CPE or GFP
expression, neutralization tests for both conventional and GFP
expression methods were done in 1,452 fresh serum samples.
Three cut-off levels for positive GFP expression were set: 1.5-, 2.0-,
and 2.5-fold increase in FU compared to cell culture controls.
Among the 1,452 samples, 1,287 (88.6%) showed the similar
neutralizing antibody titers when assayed by both methods using
the 1.5-fold cut-off, 1,367 (94.1%) with the 2.0-fold cut-off, and
1,058 (72.9%) with the 2.5-fold cut-off. Strong similarity was noted
when the cut-off was defined as a 2.0-fold of FU value in FU of the
control wells.
Effect of Heat Inactivation and Addition of Complement
Eight fresh serum samples (A–H) were obtained and stocked at
280uC. Neutralizing antibody titers were examined before freeze-
thawing, and after three and five rounds of freeze-thawing. The
results are shown in Fig. 3. For serum A, the neutralizing antibody
titer was 1:256, 1:64, and 1:128, showing no significant difference
within five rounds of freeze-thawing. It decreased to 1:8 or 1:16
after inactivation at 56uC for 30 min. The other serum showed
similar results. Neutralizing antibody titers did not decrease but
decreased after inactivation of the complement. Complement
activity would be required for neutralization tests for mumps virus.
Five fresh serum samples (A–E) were inactivated at 56uC for
30 min. When inactivated sera were used, guinea pig complement
was added to the neutralizing mixture at 1:200, 1:400, 1:800, and
1:1,600. Neutralizing antibody titers were examined and mean
values for three independent assays are shown in Fig. 4. Guinea
pig complement did not affect the assay system without any
changes in Vero cell cultures and the addition of guinea pig
complement in non-inactivated sera did not influence the
neutralizing antibody titers. The titer was 1:32–1:128 and dropped
to around 1:8 after inactivation. The reduced neutralizing
antibody titers increased to levels similar to those before
inactivation when the complement was added at 1:200 or 1:400.
Therefore, complement was added at 1:200 to the neutralizing
mixture in the subsequent experiments.
Effect of Complement
Twenty-one fresh serum samples were obtained and neutraliz-
ing antibody titers were examined for non-inactivated and
inactivated sera supplemented with complement at 1:200 in the
neutralizing mixture. The results are shown in Fig. 5. The peak
distribution of neutralizing antibody titers for non-inactivated
samples was 1:32 and shifted to 1:64, showing no significant
change in those with addition of complement.
As for the 227 stocked sera, neutralization tests were performed
before and after inactivation with the addition of complement. 74
serum samples showed negative and 70 became positive, when
assayed after inactivation with the addition of complement. The
peak distribution of neutralizing antibody titers markedly shifted
from 1:4 for non-inactivated sera (98 sera) to 1:16 after
inactivation supplemented with complement (75 sera). Stocked
sera were considered to lose complement activity over long
periods. Therefore, the addition of complement was required
when the neutralizing antibody titer was examined for the stocked
sera, probably because of decreased complement activity.
Discussion
There are several serological methods of detecting mumps
antibodies. Complement fixation (CF) and hemagglutination
inhibition (HI) tests are not sensitive and, in addition, HI
antibodies are cross-reactive to parainfluenza virus [1,10]. EIA
has high sensitivity and specificity and is a simple procedure, but is
not related to protective activity [11]. Neutralizing antibodies are
associated with protective activity but the neutralizing test involves
several complicated steps. Neutralization of an infectious virus and
the preparation of cell cultures are bothersome and most time-
consuming is the very last step to determine the appearance of
CPE in 96-well plates. For micro-neutralization assays, there are
two methods; 50% plaque reduction and complete inhibition of
CPE. There have been several reports on neutralizing tests,
concerning the evaluation of plaque reduction or inhibition of the
appearance of CPE, infectivity of a challenge virus, and
requirement of complement for neutralizing tests [12,13,14,15].
Fujino et al. [19] reported the neutralization test for measles
virus using a GFP-expressing recombinant measles virus to
evaluate the neutralizing antibody titer by Fluorescent EIA reader.
Here, a recombinant mumps Hoshino vaccine strain expressing
New Method for Mumps Neutralizing Assay
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GFP was developed to check the expression of GFP instead of
observing the appearance of CPE or plaque counting. GFP
expression was examined by a fluorescent EIA reader as fluoro-
units (FU). GFP expression increased as the virus genome was
Figure 2. Relationship between the appearance of CPE and GFP expression. Serial two-fold dilutions from 1:4 to 1:256 were mixed with an
equal volume of challenge virus. In the left panel, the schematic results of two neutralization methods are shown. CPE was observed in one of the two
wells at 1:32, and the conventional neutralizing antibody titer was 1:16 by 100% inhibition of CPE. The mean FU value of the two cell control wells
was 202 and that of the 1:32 dilution was 450, showing 1:16 of neutralizing antibody titer. Using 1,452 serum samples, the consistency of neutralizing
antibody titers was compared based on different cut-off values for GFP expression: 1.5-fold, 2.0-fold, and 2.5- fold of FU values of the cell control
wells.
doi:10.1371/journal.pone.0065281.g002
Figure 3. Effects of freeze-thawing and inactivation at 56uC for 30 min on neutralizing antibody titers. Upper panel shows the
neutralizing antibody titers of eight fresh sera (A–H), without inactivation and after three or five rounds of freeze-thawing. Lower panel shows the
results of neutralizing antibody titers after inactivation.
doi:10.1371/journal.pone.0065281.g003
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transcribed after infection and was closely related to viral growth,
as shown in Fig. 1. GFP expression in the cell control wells in a 96-
well plate was approximately 200 FU. More than a two-fold
increase in FU was considered positive for GFP expression
(presence of CPE). Neutralizing antibody titers examined by GFP
expression were similar to those by the conventional method for
100% inhibition of CPE (Fig. 2).
In several reports, the neutralizing step was performed without
the addition of complement. Hishiyama et al. [15] reported that
fresh guinea pig serum was required for neutralization tests for
mumps virus. They used complement at 1:400 dilutions in the
neutralizing mixture and the addition of complement increased
the neutralizing antibodies titers. Complement has several
important roles in immune responses and there are three main
pathways, the classical, lectin, and alternative pathways. Comple-
ment is one of the first lines of host defense and is an important
part of humoral immune responses. The complement system is
immediately ready to target and eliminate viral particles and to
interact with specific antibodies on the surface of a virus or
infected cells [20]. Complement-dependent neutralizing antibody
is reported to recognize the viral glycoproteins on the virus
envelope, directly related to neutralization of Vesicular stomatitis
virus [21,22], herpes simplex viruses [23,24], and West Nile virus
[25]. Cooper et al. [26] reported that the deposition of antibody
and complement on the surfaces of viral particles might physically
interfere with infectivity in susceptible cells due to aggregation of
the viral particles. However, Friedman et al. [23] suggested that
complement inhibited the infection process of HSV, indicating
that it affects viral replication: virus entry, uncoating, DNA
transport to the nucleus, or immediate early gene expression, not
requiring particle aggregation, viral lysis, or blocking of virus
attachment. Johnson et al. [16] investigated the requirement of a
complement system to neutralize three closely related paramyxo-
viruses, Simian virus 5 (SV5), mumps virus, and human
parainfluenza virus type 2 (HPIV2). HPIV2 was neutralized in a
complement-independent manner but neutralization of SV5 and
mumps virus proceeded through alternative pathways. However,
they were neutralized by different mechanisms; C3 deposition was
observed on the surface of SV5 particles, resulting in aggregates.
C3 deposition was also noted on the surface of mumps virus
particles but they induced virion lysis through electron microscopic
findings. In this sense, the presence of complement seemed to be
essential for the neutralization tests for mumps virus. When fresh
sera were examined for the detection of neutralizing antibodies
against mumps virus, the addition of complement did not enhance
the neutralizing antibody titers and the titers were stable for 5
rounds of freeze-thawing. But the complement activity was
reduced after inactivation and during long-term preservation,
and the addition of complement at 1:200 was required for
neutralization tests against mumps virus.
EIA is simple and a large number of serum samples are handled
without serial dilutions, which is suitable for surveillance but does
not reflect protective immunity. A purified mumps virus antigen is
used for the EIA antigen, and contains component proteins as well
as viral particles. In our previous report, neutralizing antibodies
assayed by the conventional method without complement showed
a poor relationship to EIA titers. In the present study, there was
again no significant relationship, with a low co-efficiency,
Figure 4. Neutralizing antibody titers of non-inactivated and
inactivated sera with the addition of complement. Neutralizing
antibody titers were examined in five sera (A–E) before and after
inactivation. Complement was added at 1:200, 1:400, 1:800, and 1:1600
to the neutralizing mixture when inactivated sera were used. Each
experiment was done in triplicate and mean titers were shown.
doi:10.1371/journal.pone.0065281.g004
Figure 5. Effect of the addition of complement in 21 fresh and 227 stocked serum samples. Distribution of serum samples is shown for
neutralizing antibody titers assayed without inactivation and for those assayed after inactivation with the addition of complement, using 21fresh
serum samples (left panel). 227 stocked serum samples were assayed in a similar manner (right panel).
doi:10.1371/journal.pone.0065281.g005
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examined by adding complement (data not shown). EIA-positive
sera showed positive immune-fluorescent antibodies against the
most abundant N protein [27]. Approximately 40–50% of the
serum samples positive for neutralization test showed positive for
immune-fluorescent antibodies against F or HN antigens, which
are closely related to the infection process, attachment and cell
fusion [27].
Using a recombinant mumps virus expressing GFP, the
neutralization test was simplified via a reduction in GFP
expression, counting automatically by fluorescent EIA reader.
When stocked samples were used, complement was added at a
concentration of 1:200.
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13. Nöjd J, Tecle T, Samuelsson A, Örvell C (2001) Mumps virus neutralizing
antibodies do not protect against reinfection with a heterologous mumps
genotype. Vaccine 19: 1727–1731.
14. Okuno Y, Yamanishi K, Lwin S, Takahashi M (1985) Micro-neutralization test
for mumps virus using the 96-well tissue culture plate and PAP (peroxidase-
antiperoxidase) staining technique. Microbiol Immunol 29: 327–335.
15. Hishiyama M, Tsurudome M, Ito Y, Yamada A, Sugiura A (1988)
Complement- mediated neutralization test for determination of mumps
vaccine-induced antibody. Vaccine 6: 423–427.
16. Johnson JB, Capraro G, Parks GD (2008) Differential mechanisms of
complement- mediated neutralization of closely related paramyxoviruses simian
virus 5 and mumps virus. Virology 376: 112–123.
17. Sasaki K, Higashihara M, Inoue K, Igarashi Y (1976) Studies on the
development of a live attenuated mumps virus vaccine. The Kitasato Arch
Exper Med 49: 43–52.
18. Ninomiya K, Kanayama T, Fujieda N, Nakayama T, Komase K, et al. (2009)
Amino acid substitution at position 464 in the haemagglutinin-neuraminidase
protein of a mumps virus Urabe strain enhanced the virus growth in
neuroblastoma SH-SY5Y cells. Vaccine 27: 6150–6165.
19. Fujino M, Yoshida N, Kimura K, Zhou J, Motegi Y, et al. (2007) Development
of a new neutralization test for measles virus. J Virol Methods 142: 15–20.
20. Lachmann PJ, Davies A (1997) Complement and immunity to viruses. Immunol
Rev 159: 69–77.
21. Mills BJ, Beebe DP, Cooper NR (1979) Antibody-independent neutralization of
vesicular stomatitis virus by human complement. II. Formation of VSV-
lipoprotein complexes in human serum and complement–dependent viral lysis.
J Immunol 123: 2518–2524.
22. Beebe DP, Cooper NR (1981) Neutralization of vesicular stomatitis virus (VSV)
by human complement requires a natural IgM antibody present in human
serum. J Immunol 126: 1562–1568.
23. Friedman HM, Wang L, Pangburm MK, Lambris JD, Lubinski L (2000) Novel
mechanism of antibody-independent complement neutralization of herpes
simplex virus type 1. J Immunol 165: 4528–4536.
24. Hook LM, Lubinski JM, Jiang M, Pangbum MK Friedman HM (2006) Herpes
simplex virus type 1 and 2 glycoprotein C prevents complement-mediated
neutralization induced by natural immunoglobulin M antibody. J Virol 80:
4038–4046.
25. Mehlhop E, Diamond MS (2006) Protective immune responses against West
Nile virus are primed by distinct complement activation pathways. J Exp Med
203: 1371–1381.
26. Cooper NR, Nemerow GR (1984) The role of antibody and complement in the
control of viral infections. J Invest Dermatol 83: s121–127.
27. Matsubara K, Iwata S, Nakayama T (2012) Antibodies against mumps virus
component proteins. J Infect Chemother 18: 466–471.
New Method for Mumps Neutralizing Assay
PLOS ONE | www.plosone.org 6 July 2013 | Volume 8 | Issue 7 | e65281
